Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Enanta Pharmaceuticals (ENTA) reported a Q4 loss of $1.36 per share, missing the Zacks Consensus Estimate of a $1.16 loss. This is a slight increase in loss compared to $1.33 per share a year ago.
November 25, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enanta Pharmaceuticals reported a Q4 loss of $1.36 per share, missing the expected loss of $1.16. This indicates a slight increase in losses compared to the previous year.
The reported loss per share of $1.36 is worse than the expected loss of $1.16, indicating underperformance. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100